Research Papers:
Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2685 views | HTML 5442 views | ?
Abstract
Wei-Ching Chen1,2, Yung-Sheng Chang1,2, Hui-Ping Hsu3, Meng-Chi Yen1, Hau-Lun Huang1,2, Chien-Yu Cho1,2, Chih-Yang Wang1,2, Tzu-Yang Weng1,2, Po-Ting Lai4, Ching-Shih Chen4, Yih-Jyh Lin3, Ming-Derg Lai1,2,5
1Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
3Department of Surgery, College of Medicine, National Cheng Kung University, Tainan, Taiwan
4Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA
5Center for Infectious Diseases and Signaling Research, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Correspondence to:
Ming-Derg Lai, e-mail: [email protected]
Yih-Jyh Lin, e-mail: [email protected]
Keywords: cancer stem cell marker, integrin, AMPK, mTOR, OSU-CG5
Abbreviations: HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; TGF-β-1, transforming growth factor-β-1; CSC, cancer stem cell
Received: June 09, 2015 Accepted: October 12, 2015 Published: October 22, 2015
ABSTRACT
CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5976